“This has been a transformational quarter for Capricor as we move towards potential commercialization of deramiocel for the treatment of DMD. We have commenced the submission of our BLA which we ...

The abstract will be made available on the publications section of the Capricor website.

Capricor’s stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

We expect deramiocel to be a lifelong treatment, with an infusion delivered quarterly,” added Marbán. The HOPE-2 OLE study (NCT03406780) enrolled 13 patients with DMD cardiomyopathy.

Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its ...

Capricor shares have been on the rise since late last week, when the company reported positive long-term study data for its lead asset, deramiocel, in Duchenne muscular dystrophy. The stock ...

Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy ...

Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S.

The reaffirmation follows a recent presentation at the World Muscle Society congress, highlighting the potential of Capricor's deramiocel in treating Duchenne muscular dystrophy (DMD). The ...

Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology ...